767 related articles for article (PubMed ID: 26567278)
1. Echinocandin Resistance in Candida.
Perlin DS
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S612-7. PubMed ID: 26567278
[TBL] [Abstract][Full Text] [Related]
2. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.
Perlin DS
Drugs; 2014 Sep; 74(14):1573-85. PubMed ID: 25255923
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of echinocandin antifungal drug resistance.
Perlin DS
Ann N Y Acad Sci; 2015 Sep; 1354(1):1-11. PubMed ID: 26190298
[TBL] [Abstract][Full Text] [Related]
4. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):6361-5. PubMed ID: 24060873
[TBL] [Abstract][Full Text] [Related]
5. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Alexander BD; Johnson MD; Pfeiffer CD; Jiménez-Ortigosa C; Catania J; Booker R; Castanheira M; Messer SA; Perlin DS; Pfaller MA
Clin Infect Dis; 2013 Jun; 56(12):1724-32. PubMed ID: 23487382
[TBL] [Abstract][Full Text] [Related]
6. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
Zimbeck AJ; Iqbal N; Ahlquist AM; Farley MM; Harrison LH; Chiller T; Lockhart SR
Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754
[TBL] [Abstract][Full Text] [Related]
7. The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination.
Healey KR; Nagasaki Y; Zimmerman M; Kordalewska M; Park S; Zhao Y; Perlin DS
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971865
[No Abstract] [Full Text] [Related]
8. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
[TBL] [Abstract][Full Text] [Related]
9. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
10. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW
Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous Mutational Frequency and
Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
[TBL] [Abstract][Full Text] [Related]
12. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.
Pham CD; Iqbal N; Bolden CB; Kuykendall RJ; Harrison LH; Farley MM; Schaffner W; Beldavs ZG; Chiller TM; Park BJ; Cleveland AA; Lockhart SR
Antimicrob Agents Chemother; 2014 Aug; 58(8):4690-6. PubMed ID: 24890592
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
[TBL] [Abstract][Full Text] [Related]
14. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Shields RK; Nguyen MH; Press EG; Kwa AL; Cheng S; Du C; Clancy CJ
Antimicrob Agents Chemother; 2012 Sep; 56(9):4862-9. PubMed ID: 22751546
[TBL] [Abstract][Full Text] [Related]
15. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.
Beyda ND; Lewis RE; Garey KW
Ann Pharmacother; 2012; 46(7-8):1086-96. PubMed ID: 22811350
[TBL] [Abstract][Full Text] [Related]
16. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
17. Clinical perspectives on echinocandin resistance among Candida species.
Shields RK; Nguyen MH; Clancy CJ
Curr Opin Infect Dis; 2015 Dec; 28(6):514-22. PubMed ID: 26524326
[TBL] [Abstract][Full Text] [Related]
18. Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species.
Marcos-Zambrano LJ; Gómez-Perosanz M; Escribano P; Zaragoza O; Bouza E; Guinea J
Antimicrob Agents Chemother; 2016 Jun; 60(6):3579-86. PubMed ID: 27021323
[TBL] [Abstract][Full Text] [Related]
19. Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer CD; Garcia-Effron G; Zaas AK; Perfect JR; Perlin DS; Alexander BD
J Clin Microbiol; 2010 Jul; 48(7):2373-80. PubMed ID: 20421445
[TBL] [Abstract][Full Text] [Related]
20. Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.
Shields RK; Nguyen MH; Press EG; Cumbie R; Driscoll E; Pasculle AW; Clancy CJ
Antimicrob Agents Chemother; 2015 Dec; 59(12):7465-70. PubMed ID: 26392494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
